MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Current Ratio 2011-2026 | BMY
Annual Current Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.26 | 1.22 | 1.45 | 1.47 | 1.49 | 1.47 | 1.6 | 1.61 | 1.55 | 1.55 | 1.3 | 1.73 | 1.52 | 1.15 | 1.97 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.97 | 1.15 | 1.49 |
Quarterly Current Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.23 | 1.23 | 1.22 | 1.22 | 1.2 | 1.47 | 1.52 | 1.51 | 1.47 | 1.5 | - | 1.44 | 1.49 | 1.51 | 1.5 | 1.5 | 1.47 | 1.47 | 1.47 | 1.47 | 1.66 | 1.66 | 1.66 | 1.66 | 1.68 | 1.68 | 1.68 | 1.68 | 1.55 | 1.55 | 1.55 | 1.55 | 1.94 | 1.94 | 1.94 | 1.94 | 1.83 | 1.83 | 1.83 | 1.83 | 1.8 | 1.8 | 1.8 | 1.8 | 1.65 | 1.65 | 1.65 | 1.65 | 1.61 | 1.61 | 1.61 | 1.61 | 1.93 | 1.93 | 1.93 | 1.93 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 | 1.2 | 1.63 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
2.53 | $ 8.71 | 0.81 % | $ 86.1 M |  USA |
 |
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
7.02 | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
2.84 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
BioNTech SE
BNTX
|
7.95 | $ 99.4 | 2.79 % | $ 27.2 B | Germany |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
0.0929 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
0.762 | - | - | $ 8.42 M | USA |
 |
Burford Capital Limited
BUR
|
2.14 | $ 4.72 | 5.23 % | $ 756 M |  Britain |
 |
Cabaletta Bio
CABA
|
3.11 | $ 3.24 | 1.09 % | $ 326 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
1.46 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
2.68 | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 21.6 | 1.12 % | $ 1.01 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
0.372 | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
0.681 | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.22 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
1.09 | $ 1.54 | 4.77 % | $ 396 M | USA |
 |
Evogene Ltd.
EVGN
|
2.48 | $ 0.82 | -0.2 % | $ 27.9 M |  Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 3.11 | 6.51 % | $ 5.12 M | Israel |
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.2 | 0.24 % | $ 449 M | USA |
|
Forte Biosciences
FBRX
|
3.8 | $ 34.19 | 11.75 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
1.78 | $ 25.23 | 4.6 % | $ 3.21 B | USA |
 |
Chimerix
CMRX
|
10.8 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
3.11 | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
10.4 | $ 33.56 | 2.98 % | $ 2.23 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.43 | $ 1.49 | 1.02 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
0.269 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
4.17 | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
15.9 | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
2.1 | $ 2.46 | -2.19 % | $ 1.09 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | Israel |
 |
Galectin Therapeutics
GALT
|
0.134 | $ 2.49 | 5.74 % | $ 159 M | USA |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |